Harnessing TLR2 Agonism to Reprogram Tumor-Associated Myeloid Cells: Insights from Axelia Oncology

Time: 12:00 pm
day: Conference Day Two

Details:

• Showcasing Axelia’s approach to shifting immunosuppressive myeloid cells toward a pro-inflammatory, anti-tumor phenotype
• Sharing key data on pharmacodynamics, immune activation, and tumor microenvironment remodeling
• Discussing patient stratification strategies and next steps in clinical evaluation of TLR2-based immunotherapy

Speakers:

Anna Galkin Dr. Anna Galkin is the Chief Scientific Officer at Axelia Oncology, where she leads efforts to develop novel immunotherapies that reprogram macrophages for anti-tumor activity. Read more